May 12, 2021
0 0

About a third of patients after a mild course of COVID-19 begin to take new drugs

The study, published in The Lancet Infectious Diseases, compared the health data of 9,000 Danish people with confirmed COVID-19 with 81 citizens who received a negative PCR test between February and May 2020. The average age of patients was 43 years, 63.5% were women.

The group of infected included only patients who did not have serious complications and were treated on an outpatient basis. Both groups were followed up by their physicians from two weeks to six months after testing. The study authors noted that all patients, both with and without COVID-19, had comparable risks of developing various diseases.

The results showed that people who underwent coronavirus were more likely to be diagnosed with breathing problems, as well as cases of venous thromboembolism. The analysis also showed that 31% of patients within six months after COVID-19 were forced to start taking new drugs, including bronchodilators to eliminate shortness of breath and drugs to relieve migraines.

In addition, compared with their peers who managed to avoid contracting the coronavirus, such patients visit their doctors 1.2 times more often. At the same time, the authors of the study found no statistical difference in the assessment of cases of emergency hospitalization in both groups.

According to the study’s lead author, Anton Pottegard, M.D., of the University of Southern Denmark, most of the research on postcoid conditions is carried out mainly among hospitalized patients, while even people who have had the infection very easily suffer from the long-term consequences.

“Our study highlights the need to provide physicians with the resources to support any potential long-term conditions in all patients,” he said.

Article Categories:

Leave a Reply